# Zentera Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zentera-therapeutics

- Industry: Pharmaceuticals
- Headquarters: New York, US
- Website: www.zentalis.com
- Total disclosed funding: $95M
- Latest round: Series B (Aug 2, 2021)
- Investors on record: 11

## About

Zentera Therapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of innovative small molecule therapeutics targeting cancer by disrupting critical biological pathways.Founded in 2020 and headquartered in New York, US, Zentera Therapeutics, Inc. specializes in cancer therapeutics. The company raised USD 75 mn in Series B funding on August 2, 2021, with prominent investors including OrbiMed Advisors and Tybourne Capital Management. The company has completed two deals to date.Zentera Therapeutics focuses on developing small molecule therapeutics aimed at treating cancer. Their lead product, Azenosertib, is designed to specifically address various cancer indications by altering cancer cell functions. The company primarily supplies these therapeutics to healthcare providers and oncology specialists in the US and selected international markets.Zentera Therapeutics generates revenue through pharmaceutical partnerships and collaborations, especially from the commercialization of Azenosertib. Their revenue is primarily derived from licensing agreements and milestone payments tied to clinical development and regulatory approvals of their products, facilitating transactions with healthcare systems and oncology clinics.Zentera Therapeutics plans to leverage recent funding to advance the development of Azenosertib and explore additional therapeutic products targeting unmet medical needs in oncology. The recent Series B funding of USD 75 mn will support their growth initiatives as they aim to expand their market presence in North America and select international regions by 2023.

## Funding rounds

- Series B, Aug 2, 2021, $75M — OrbiMed Advisors, Viking Global Investors, Lilly Asia Ventures, Redmile Group, Casdin Capital, Farallon Capital Management, Perceptive Advisors, Surveyor Capital, Logos Capital, Avidity Partners, Tybourne Capital Management
- Series A, May 21, 2020, $20M — OrbiMed Advisors, Tybourne Capital Management

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- Tybourne Capital Management (https://capitalatlas.ai/funds/tybourne-capital-management) — Series A, Series B
- Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series B
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series B
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series B
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series B
- Farallon Capital Management (https://capitalatlas.ai/funds/farallon-capital-management) — Series B
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B
- Surveyor Capital — Series B
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series B
- Avidity Partners — Series B